C Spire Named 2025 Southeast Partner of the Year by Arctic Wolf
'We are honored to be recognized as Arctic Wolf Southeast Partner of the Year and look forward to delivering even more cybersecurity innovation and value for our customers,' said Drake Cushing, SVP and General Manager for C Spire Business.
Share
'We are honored to be recognized as Arctic Wolf Southeast Partner of the Year and look forward to delivering even more cybersecurity innovation and value for our customers,' said Drake Cushing, Senior Vice President and General Manager for C Spire Business. 'Cybersecurity threats and their constant advancement in attack methods continue to grow and require forward-focusing technology to protect businesses. Through our partnership with Arctic Wolf, C Spire continues to deliver advanced technology our customers need and expect from us.'
The Arctic Wolf Partner of the Year Awards recognize elite partners who have demonstrated outstanding leadership in helping organizations improve their security operations through Arctic Wolf's portfolio of solutions. Now in their eighth year, the honors celebrate top-performing companies that have shown excellence in security practice, executive alignment, revenue growth, and service.
'This year's award winners represent the very best of the Arctic Wolf partner community,' said Will Briggs, Senior Vice President, Global Channels, Arctic Wolf. 'Each of these organizations has demonstrated exceptional commitment to our shared mission to end cyber risk, helping customers navigate an increasingly complex threat landscape with confidence and resilience. We're proud to recognize their achievements and celebrate the critical role they play in driving meaningful security outcomes.'
C Spire Business is a division of C Spire, a diversified telecommunications and technology services provider. C Spire has highly certified IT engineering talent in markets across the Southeast U.S. and specializes in connecting businesses of all sizes with best-in-class solutions. Cloud, collaboration, cybersecurity, managed IT, fiber connectivity — C Spire Business delivers all the power and expertise organizations need to win.
As organizations worldwide face an increasingly complex threat landscape and a persistent cybersecurity talent shortage, over 10,000 organizations globally now rely on the Arctic Wolf Aurora Platform to help end cyber risk. Built on an open-XDR architecture and powered by Alpha AI™ technologies, the Aurora Platform is designed to deliver positive security outcomes at scale. Each week, it ingests, parses, enriches, and analyzes over eight trillion security events—transforming overwhelming volumes of data into an average of just one actionable alert per customer per day.
Additional Resources
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
Commercial trial demonstrates SaFeGuard's™ effectiveness in processing opportunity crudes HOUSTON, August 20, 2025--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. "We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations," said Ketjen's Chief Commercial Officer Henri Tausch. "This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers." "SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon," said David Leach, Vice President and General Manager, FCC at Ketjen. "It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement." Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit View source version on Contacts Media Contact: Jennifer Albert, MediaRelations@ Sign in to access your portfolio
Business Wire
8 hours ago
- Business Wire
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
HOUSTON--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. 'We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations,' said Ketjen's Chief Commercial Officer Henri Tausch. 'This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers.' 'SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon,' said David Leach, Vice President and General Manager, FCC at Ketjen. 'It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement.' Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit
